Building Successful Market Access Strategies from Day One - BioPharma Unscripted Ep. 6

BioPharma Unscripted!

Building Successful Market Access Strategies from Day One - BioPharma Unscripted Ep. 6

In this episode of BioPharma Unscripted!, host Marcus speaks with pharmaceutical market access expert Ana Filipa Alexandre, PharmD, MPH about the critical importance of early access planning in drug development.

Ana shares insights from her extensive career spanning regulatory affairs, health economics, and market access, explaining why companies must consider access strategies from the earliest stages of development.

In This Episode You'll Learn

• What market access truly encompasses beyond regulatory approval
• Why companies frequently fail to start market access planning early enough
• How to build a compelling "value story" with evidence-based value propositions
• The specific consequences when market access planning is inadequate
• Special considerations for small biotech companies with limited resources
• The critical relationship between health economics and market access functions
• Why post-launch market access activities remain important throughout a product's lifecycle
• How the upcoming Joint Clinical Assessment (JCA) might impact European market access

Whether you're a pharmaceutical professional, biotech entrepreneur or healthcare policy expert, this episode offers valuable insights into how successful drugs make the journey from lab to patient.

Ana Filipa Alexandre, PharmD, MPH: Ana is a pharmacist by training with extensive experience in market access across affiliate and global roles. Connect with Ana on LinkedIn: https://www.linkedin.com/in/ana-filipa-alexandre-pharmd-mph/

Chapters

00:00 Introduction and Ana's background

01:31 Ana's journey into pharmaceutical market access

02:25 Defining market access as a process

04:44 Why companies fail to start market access planning early

07:06 Cross-functional collaboration in market access

08:26 Building the value story for new products

11:04 Challenges for small biotech companies

13:24 Example of effective early access planning

16:38 Advice for early-stage biotechs on market access

19:40 The role of consultants vs in-house expertise

21:42 Consequences of inadequate market access planning

24:16 Career development in market access

27:11 Post-launch considerations in market access

29:19 Concluding remarks

Connect with Marcus and Elucid8: https://www.linkedin.com/in/marcus-metcalfe-8938a35/ Marcus helps US & European Biotech & Pharmaceutical clients by providing Interim/Fractional & Advisory consultants for operational & strategic needs.

I also work selective Executive Search (perm) projects.
I have helped Clients when there is no headcount, when they can't find the right permanent candidate, when they have a spike in business, as an alternative to an external vendor or for those simply needing an extra pair of hands.
If you need a partner with an extensive network in HEOR and Market Access - this is his sweet spot.

He has placed over 120 HEOR and Market Access candidates during my time across US and Europe.
With his business partners, he covers the below functional areas.
• Biometrics • Business Development
• Clinical Research • Drug safety & Product safety
• Engineering • Health Economics
• Medical Affairs • Market Access
• Regulatory Affairs • Compliance/Quality Assurance
• Marketing & Medical • Scientific & Preclinical
• Communications

Sponsor Message

This episode is brought to you by www.elucid8.co - Connecting Talent, Strategy, and Investment to Transform Life Sciences

Podcast produced by www.podforge.co.uk